50289-06-0

Basic information

• Product Name: 4-Piperidinecarboxylic acid, 4-hydroxy-
• Synonyms: 4-Piperidinecarboxylic acid, 4-hydroxy-;4-hydroxy-4-piperidinecarboxylic acid
• CAS NO: 50289-06-0
• Molecular Formula: C₆H₁₁NO₃
• Molecular Weight: 145.15644
• Mol File: 50289-06-0.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 4-Piperidinecarboxylic acid, 4-hydroxy-(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Piperidinecarboxylic acid, 4-hydroxy-(50289-06-0)
• EPA Substance Registry System: 4-Piperidinecarboxylic acid, 4-hydroxy-(50289-06-0)

Safety Data

• Hazardous Substances Data: 50289-06-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Piperidinecarboxylic acid, 4-hydroxyis used as a building block for the synthesis of pharmaceuticals, due to its unique structure and properties.
Used in Biochemical Research:
4-Piperidinecarboxylic acid, 4-hydroxyis used in biochemical research for its role in the structure and function of collagen.
Used in Collagen-based Products:
4-Piperidinecarboxylic acid, 4-hydroxyis used in the production of collagen-based products such as skin creams and supplements, due to its importance in collagen structure and function.
Used in Drug Development:
4-Piperidinecarboxylic acid, 4-hydroxyhas potential applications in the development of new drugs for treating various medical conditions, leveraging its unique properties and interactions.

Upstream product

• 235100-95-5 1-carbethoxy-4-cyano-4-hydroxypiperidine 
• 59119-18-5 1-benzyl-4-hydroxypiperidine-4-carboxylic acid 
• 6094-60-6 1-benzyl-4-hydroxypiperidine-4-carbonitrile 

Downstream Products

• 67117-20-8 1-benzyloxycarbonyl-4-hydroxypiperidine-4-carboxylic acid 
• 1580440-41-0 1-(4-(4-fluorophenyl)pyrimidin-2-yl)-4-hydroxypiperidine-4-carboxylic acid 

Relevant articles and documents

Structure-Guided Optimization Provides a Series of TTK Protein Inhibitors with Potent Antitumor Activity

TTK is an essential spindle assembly checkpoint enzyme in many organisms. It plays a central role in tumor cell proliferation and is aberrantly overexpressed in a wide range of tumor types. We recently reported on a series of potent and selective TTK inhibitors with strong antiproliferative activity in triple negative breast cancer (TNBC) cell lines (8: TTK IC50 = 3.0 nM; CAL-51 IC50 = 84.0 nM). Inspired by previously described potent tricyclic TTK inhibitor 6 (TTK IC50 = 0.9 nM), we embarked on a structure-enabled design and optimization campaign to identify an improved series with excellent potency, TTK selectivity, solubility, CYP inhibition profile, and in vivo efficacy in a TNBC xenograft model. These efforts culminated in the discovery of 25 (TTK IC50 = 3.0 nM; CAL-51 IC50 = 16.0 nM), which showed significant single-agent efficacy when dosed iv in a TNBC xenograft model without body weight loss.

ANTIBACTERIAL COMPOUNDS

The present invention provides a compound of the following formula and salts thereof: Also provided is the use of these compounds as antibacterials, compositions comprising them and processes for their manufacture.

Phosphonic acid derivatives having carboxypeptidase b inhibitory activity

A compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof: wherein R1represents hydrogen atom, an alkyl group, a substituted alkyl group and the like; R2and R3represent hydrogen atom, an alkyl group, a substituted alkyl group, an alkoxyl group and the like; X represents —CH2—, —O—, or —NH—; A represents the following group (II): [in which R7and R8represent hydrogen atom, an alkyl group, an acyl group, an alkoxycarbonyl group and the like; R9and R10represents hydrogen atom, a halogen atom, hydroxyl group, phenyl group, an alkyl group and the like] and the like; and E represents hydrogen atom and the like, which has inhibitory activity against carboxypeptidase B and is useful for therapeutic and/or preventive treatment of a thrombotic disease.

GABA agonists. Synthesis and structure-activity studies on analogues of isoguvacine and THIP

A series of analogues of the specific GABA receptor agonists isoguvacine, isonipecotic acid, and THIP (4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol) have been synthesized and tested as inhibitors of the binding of 3H-GABA to GABA receptor sites on rat brain membranes in vitro. Introduction of a hydroxy group into the 3- or 4-position of isonipecotic acid results in compounds with considerably reduced receptor affinity. The 7-membered ring analogues of isoguvacine and isonipecotic acid are more than two orders of magnitude weaker than the parent compounds. Replacement of the 3-isoxazolol unit of THIP by related heterocyclic rings also result in dramatic loss of activity. Thus iso-THIP (4,5,6,7-tetrahydroisoxazolo[3,4-c]pyridin-3-ol) is a weak inhibitor of 3H-GABA binding, whereas the 3-pyrazolol THIP analogues are inactive.